A new molecular scissors act like a GPS to improve genome editing
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, a new molecular scissors unzip and cleave DNA. This member of the CRISPR-Cas family displays a high accuracy, capable of acting like a GPS in order to identify its destination within the intricate map of the genome. The high precision of Cpf1 will improve the use of this type of technology in repairing genetic damage and in other medical and biotechnological applications.
A scientific team from in the Novo Nordisk Foundation Center for Protein Research (NNF-CPR), at the University of Copenhagen, has succeeded in visualizing and describing how a new system for genome editing, known as Cpf1, works. This protein belongs to the Cas family and enables the cleavage of double stranded DNA, thus allowing the initiation of the genome modification process. The results of the study have been published in the journal Nature.
Guillermo Montoya, a researcher in the fields of biochemistry and molecular biology who led the study, explains to SINC that the new molecular scissors “will enable us to more safely modify and edit the instructions written in the genome, due to the utmost precision of the target DNA sequence recognition”.
The new molecular scissors achieve complementary ends instead of blunt, as happens with Cas9, which facilitates the insertion of a DNA sequence
The CRISPR Cas9 system for cutting and paste genome sequences is already being used to modify animal and plant genomes. Also to treat illnesses, such as cancer and retinal diseases, in humans and its applications are growing very fast.
X-Ray Crystallography Technique
Researchers across the world are trying to perfect this genome editing technique with the aim of making it yet more precise and efficient. To achieve this, they have also focused on other proteins that specifically cut DNA, such as Cpf1, whose manipulation can direct them to specific locations in the genome. Montoya’s team has achieved this using an X-ray Crystallography to decipher the molecular mechanisms controlling this process.
“We radiated the crystals of the Cpf1 protein using X-rays to be able to observe its structure at atomic resolution, enabling us to see all its components,” points out the co-author of this study. “X-ray diffraction is one of the main biophysical techniques used to elucidate biomolecular structures,” he continues.
In his opinion, “the main advantage of Cpf1 lies in its high specificity and the cleaving mode of the DNA, since it is possible to create staggered ends with the new molecular scissors, instead of blunt-ended breaks as is the case with Cas9, which facilitates the insertion of a DNA sequence.”
“The high precision of this protein recognising the DNA sequence on which it is going to act functions like a GPS, directing the Cpf1 system within the intricate map of the genome to identify its destination. In comparison with other proteins used for this purpose, it is also very versatile and easy to be reprogrammed,” Montoya adds.
The high precision DNA sequence recognition functions as a GPS that directs the tool within the intricate map of the genome
Genetic diseases and tumours
These properties make this system “particularly suitable for its use in the treatment of genetic diseases and tumours,” he affirms.
The team has previously worked with the French biotechnology company Celletics on the use of meganucleases –other proteins that can be redesigned to cut the genome in a specific location– to treat certain types of leukemia.
The new technology “can also be used to modify microorganisms, with the aim of synthesising the metabolites required in the production of drugs and biofuels,” adds Montoya.
This researcher, from Getxo (Biscay, Spain), says that there are many companies interested in this new technology. They are mostly from the biotechnology sector in the field of microorganism manipulation, but cannot be named due to confidentiality agreements.
The Latest on: Genome editing
- Max Planck Society publishes discussion paper on genome editingon October 16, 2019 at 3:18 am
In its discussion paper, the Ethics Council of the Max-Planck-Gesellschaft deals with various fields of application and aspects of genome editing. The authors of the individual chapters use the ...
- “The Ethics of Human Genome Editing” Special Issue Published in CRISPR Journalon October 15, 2019 at 2:48 pm
Click here to read the full-text issue free on The CRISPR Journal. The issue contains 11 articles: nine Perspectives and two research articles on issues including human rights for the unborn, the ...
- Genome-editing study raises hopes for 'curing' cervical canceron October 14, 2019 at 7:17 am
Australian researchers have successfully halted and eliminated cancer growth in tumour-bearing mice by injecting them with nanoparticles containing genome editing machinery targeting cancer genes.
- Media alert: New articles on the ethics of genome editing published in The CRISPR Journalon October 11, 2019 at 11:59 am
In the opening Perspective of the special issue on The Ethics of Human Genome Editing, Stanford Law professor Henry Greely argues that germline editing is not inherently bad or unethical, but the ...
- NBMA begins drafting of guidelines on genome editing regulationon October 11, 2019 at 12:21 am
The National Biosafety Management Agency (NBMA) has begun drafting of guidelines for the proper regulation of genome editing in Nigeria. The Director-General/CEO NBMA, Dr Rufus Ebegba, while speaking ...
- NBMA drafts guidelines for genome editingon October 10, 2019 at 11:29 pm
The National Biosafety Management Agency (NBMA) has begun drafting of guidelines for the proper regulation of genome editing in Nigeria. The Director-General/Chief Executive Officer, Dr. Rufus Ebegba, ...
- bluebird Inks Genome Editing Research Deal With Novo Nordiskon October 10, 2019 at 11:56 am
bluebird bio, Inc. BLUE announced that it has entered into a research collaboration agreement with Denmark’s Novo Nordisk A/S NVO for jointly developing next-generation in vivo genome editing ...
- Novo Nordisk, bluebird bio partner on genome editing in hemophiliaon October 10, 2019 at 11:10 am
A biotech company developing cell and gene therapies for blood cancers and hematological disorders is partnering with a European company to develop genome-editing technology for genetic diseases.
- Bluebird, Novo Nordisk to collaborate on genome editing project, starting with hemophiliaon October 9, 2019 at 9:36 pm
Bluebird Bio Inc. and Novo Nordisk A/S plan to develop in vivo genome editing treatments for genetic diseases, including hemophilia, over the next three years.
- bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseon October 9, 2019 at 5:00 am
CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly ...
via Google News and Bing News